GlucoTrack, Inc. - Common Stock (GCTK)
2.5600
+0.5300 (26.11%)
NASDAQ · Last Trade: Sep 24th, 12:56 PM EDT
Detailed Quote
| Previous Close | 2.030 |
|---|---|
| Open | 2.430 |
| Bid | 2.560 |
| Ask | 2.570 |
| Day's Range | 2.380 - 3.250 |
| 52 Week Range | 1.998 - 136.29 |
| Volume | 48,421,540 |
| Market Cap | 2.33M |
| PE Ratio (TTM) | -0.0009 |
| EPS (TTM) | -2,786.0 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,331,771 |
Chart
About GlucoTrack, Inc. - Common Stock (GCTK)
GlucoTrack, Inc. is a healthcare technology company focused on the development of innovative non-invasive glucose monitoring solutions for individuals with diabetes. The company leverages advanced sensing technologies to create devices that enable users to track their blood glucose levels without the need for traditional fingerstick methods. GlucoTrack aims to improve the quality of life for diabetic patients by providing them with more convenient and accessible ways to manage their condition, while also enabling healthcare providers to better monitor patient health. Through its commitment to research and development, GlucoTrack seeks to contribute to more effective diabetes management and enhance overall patient outcomes. Read More
News & Press Releases
Which stocks are moving on Thursday?chartmill.com
Via Chartmill · September 24, 2026
The market is filled with gapping stocks in Thursday's session.chartmill.com
Via Chartmill · September 24, 2026
Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,350,220 shares of common stock at a price of $2.039 per pre-funded warrant. The Company expects to receive aggregate gross proceeds of approximately $3,100,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 25, 2026, subject to the satisfaction of customary closing conditions.
By Glucotrack, Inc. · Via Business Wire · September 24, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · September 24, 2026
Stay updated with the stocks that are on the move in today's after-hours session.chartmill.com
Via Chartmill · September 23, 2026
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblastoma (GBM) and other brain tumors, has engaged two ai² PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and development. Innovate GBM is the first external organization to secure access to the Lōkahi proprietary asset identification process, which is implemented through its current 14 university collaborations. This engagement marks the ai² Division’s evolution from an internal asset discovery engine to a model capable of supporting the strategic interests of outside organizations.
By Lōkahi Therapeutics · Via Business Wire · September 23, 2026
Lōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets.
By Lōkahi Therapeutics · Via Business Wire · September 23, 2026
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business development and asset assessment opportunities. The program also supports Lōkahi’s strategy of identifying and evaluating promising therapeutic assets that may have been overlooked or are no longer being actively developed.
By Lōkahi Therapeutics · Via Business Wire · September 18, 2026
Top movers in Friday's sessionchartmill.com
Via Chartmill · September 11, 2026
Let's have a look at the top gainers and losers in the middle of the day of today's session.chartmill.com
Via Chartmill · September 11, 2026
Traders are paying attention to the gapping stocks in Friday's session.chartmill.com
Via Chartmill · September 11, 2026
Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount. The financing is structured as convertible debt with an initial conversion price of $3.12 per share. In connection with the financing, investors will also receive warrants exercisable at $7.50 per share.
By Glucotrack, Inc. · Via Business Wire · September 11, 2026
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the expansion of its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. The new structure reflects the growth of the Company's actual intelligence-driven platform and is designed to create opportunities for revenue generation while continuing to advance Lōkahi's core pharmaceutical development strategy.
By Lōkahi Therapeutics Inc. · Via Business Wire · September 8, 2026
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening Lōkahi’s growing network of partner academic institutions. The partnership with SDSU furthers Lōkahi’s work to identify and evaluate promising drug candidates and technologies that may have been overlooked or are no longer being actively developed. The program also supports Lōkahi’s efforts to explore potential new treatments while giving student participants practical experience addressing business challenges in the biopharmaceutical industry.
By Lōkahi Therapeutics · Via Business Wire · September 2, 2026
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a healthcare technology and biopharmaceutical company operating Lōkahi Therapeutics™, today announced that it will effect a 1-for-15 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, August 31, 2026.
By Glucotrack, Inc. · Via Business Wire · August 27, 2026
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company's lead development candidate for osteoarthritis pain.
By Lōkahi Therapeutics Inc. · Via Business Wire · August 25, 2026
Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed collaboration expands Lōkahi’s growing nationwide network of academic institutions contributing to the identification and evaluation of underdeveloped, overlooked, or strategically deprioritized therapeutic assets. The program functions as a capital-efficient component of Lōkahi’s asset origination and evaluation process while providing students with direct experience addressing real-world biopharmaceutical business challenges.
By Lōkahi Therapeutics · Via Business Wire · August 21, 2026
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved upwards by
Via Benzinga · August 17, 2026
Glucotrack, Inc. (Nasdaq: GCTK) today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel has confirmed that Glucotrack has regained compliance with Nasdaq's stockholders' equity requirement. The decision represents an important milestone in the Company's efforts to strengthen its foundation and position for future growth.
By Glucotrack, Inc. · Via Business Wire · August 17, 2026
Glucotrack, Inc. (NASDAQ: GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in the form of convertible debt.
By Glucotrack · Via Business Wire · August 5, 2026
What's going on in today's after hours sessionchartmill.com
Via Chartmill · August 4, 2026
Please replace the release dated July 31, 2026, with the following corrected version due to multiple minor revisions.
By Lōkahi Therapeutics Inc. · Via Business Wire · August 3, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · July 31, 2026
Top stock movements in today's session.chartmill.com
Via Chartmill · July 31, 2026
Thursday's after hours session: top gainers and loserschartmill.com
Via Chartmill · July 30, 2026